Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan ...
Discontinuing GLP-1 treatment does not always cause significant weight gain, as many patients transition to other obesity or diabetes treatments, according to a Cleveland Clinic study published March ...
The analysis does not include details about why patients quit. But it does offer a longer view on the real-world experiences of patients taking the drugs than previous research that studied use over a ...
The clinical trials told one story. When patients stopped semaglutide in controlled research settings, they regained roughly two-thirds of their lost weight within a year. When tirzepatide was ...
A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or try alternative therapies, helping explain why average weight regain after ...
July 10 (Reuters) - Only one in four U.S. patients prescribed Novo Nordisk’s (NOVOb.CO), opens new tab Wegovy or Ozempic for weight loss were still taking the popular medications two years later, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results